Russian covid-19 vaccine was highly effective in trial, boosting Moscow’s rollout ambitions
This picture taken on February 1, 2021, shows vials of Russian Sputnik V vaccine in Belgrade Fair turned into a vaccination centre. - Serbia continues a mass Covid-19 vaccination campaign and became the first European country to use Chinese-made Sinopharm vaccine, after receiving one million doses of the Sinopharm vaccine, on January 16, 2021. Beside the Chinese made jab, Serbian citizens can choose to receive either Sputnik V Gam-COVID-Vac or Pfizer-BioNTech Covid-19 vaccine. (Photo by OLIVER BUNIC / AFP)
(AFP)
Georgi Kantchev
, The Wall Street Journal
Share Via
Read Full Story
MOSCOW Russia’s homegrown Sputnik V vaccine showed high levels of efficacy and safety in a peer-reviewed study, handing Moscow a geopolitical coup and a potential slice of the multibillion-dollar vaccine market as it seeks to promote the Covid-19 shot abroad and curb the pandemic at home.
What Russia s Sputnik V vaccine means for the UK
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Russia s Covid-19 vaccine 92% effective
Sputnik V is the third vaccine which is over 90% effective in Phase III trial
Reuters
February 02, 2021
A medical worker demonstrates a vial with Sputnik V (Gam-Covid-Vac) vaccine during the vaccination against the coronavirus disease (Covid-19) at a clinic in Moscow, Russia December 5, 2020. PHOTO: REUTERS/FILE
MOSCOW:
Scientists gave Russia s Sputnik V vaccine the green light on Tuesday saying it was almost 92% effective in fighting Covid-19 based on peer-reviewed late-stage trial results published in The Lancet international medical journal.
Experts said the Phase III trial results meant the world had another effective weapon to fight the deadly pandemic and justified to some extent Moscow s decision to roll out the vaccine before final data had been released.
Russia s Sputnik V vaccine 91.6% effective in late-stage trial Reuters 2/2/2021
By Polina Ivanova
MOSCOW, Feb 2 (Reuters) - Russia s Sputnik V vaccine was 91.6% effective in preventing people from developing COVID-19, according to peer-reviewed results from its late-stage clinical trial published in The Lancent international medical journal on Tuesday.
Scientists said the Phase III trial results meant the world had another effective weapon to fight the deadly pandemic and justified to some extent Moscow s decision to roll out the vaccine before final data had been released.
The results, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, were in line with efficacy data reported at earlier stages of the trial, which has been running in Moscow since September.
Russia s Sputnik V Vaccine 92% Effective In Fighting COVID-19, Study Says
Moscow was criticized for rolling out the vaccine before final data had been released.
Polina Ivanova
MOSCOW (Reuters) Scientists gave Russia’s Sputnik V vaccine the green light on Tuesday saying it was almost 92% effective in fighting COVID-19 based on peer-reviewed late-stage trial results published in The Lancet international medical journal.
Experts said the Phase III trial results meant the world had another effective weapon to fight the deadly pandemic and justified to some extent Moscow’s decision to roll out the vaccine before final data had been released.
The results, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, were in line with efficacy data reported at earlier stages of the trial, which has been running in Moscow since September.
vimarsana © 2020. All Rights Reserved.